Loading
An antibody carrying a chemotherapy payload shrank 45 percent of HER2-positive bowel cancers that had already failed two or more treatments, including tumours that had progressed on other HER2 drugs.
Siena, Di Bartolomeo, Raghav and colleagues recruited patients from 25 clinics and hospitals in Italy, Japan, Spain, the United Kingdom and the United States with centrally confirmed HER2-expressing metastatic colorectal cancer that had progressed on two or more previous regimens, RAS and BRAF V600E wild-type tumours and ECOG score 0 or 1; previous HER2-targeted therapy other than trastuzumab deruxtecan was permitted. Patients were enrolled into three cohorts by HER2 expression level and received 6.4 mg/kg trastuzumab deruxtecan intravenously every three weeks. The primary endpoint was confirmed objective response in cohort A by independent central review.
Between February 2018 and July 2019, 78 patients were enrolled: 53 in cohort A (HER2-positive), seven in cohort B and 18 in cohort C.
The antibody-drug conjugate route into HER2-positive colorectal cancer, extended by DESTINY-CRC02 at a lower dose; interstitial lung disease is the class risk that defines how the drug is monitored.
Shares Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES), HER2-amplified colorectal cancer, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, HER2 and the tag colorectal-evidence.
Shares Takayuki Yoshino, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Toxicity and quality of life are undervalued, Colorectal cancer and the tag colorectal-evidence.
Shares Takayuki Yoshino, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Toxicity and quality of life are undervalued, Colorectal cancer and the tag colorectal-evidence.
Shares Takayuki Yoshino, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Toxicity and quality of life are undervalued, Colorectal cancer and the tag colorectal-evidence.
Shares Takayuki Yoshino, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Colorectal cancer and the tag colorectal-evidence.
Shares Takayuki Yoshino, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Colorectal cancer and the tag colorectal-evidence.
Shares Salvatore Siena, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Colorectal cancer and the tag colorectal-evidence.
Shares Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, The Lancet Oncology, Colorectal cancer and the tag colorectal-evidence.